Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASCEND: Cabotegravir PrEP in People Who Inject Drugs
NCT07199335Phase 4Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of cabotegravir in human immunodeficiency virus infection (HIV), sponsored by Massachusetts General Hospital. Started Feb 2026; status: recruiting.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07199335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07199335.